BlackRock Fund Advisors’s Esperion Therapeutics ESPR Stock Holding History

BlackRock Fund Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9.88M	Buy	789,210 +90,435	+13%	+$1.08M	﹤0.01%	2579
2016 Q3	$9.68M	Buy	698,775 +40,856	+6%	+$463K	﹤0.01%	2488
2016 Q2	$6.5M	Buy	657,919 +51,577	+9%	+$855K	﹤0.01%	2656
2016 Q1	$10.3M	Buy	606,342 +17,453	+3%	+$281K	﹤0.01%	2328
2015 Q4	$13.1M	Buy	588,889 +275,432	+88%	+$6.95M	﹤0.01%	2293
2015 Q3	$7.39M	Sell	313,457 -408	-0.1%	-$25.6K	﹤0.01%	2559
2015 Q2	$25.7M	Buy	313,865 +127,173	+68%	+$12.4M	0.01%	1955
2015 Q1	$17.3M	Buy	186,692 +12,041	+7%	+$777K	﹤0.01%	2141
2014 Q4	$7.06M	Sell	174,651 -131,276	-43%	-$4.02M	﹤0.01%	2671
2014 Q3	$7.48M	Buy	305,927 +1,300	+0.4%	+$20.7K	﹤0.01%	2523
2014 Q2	$4.83M	Sell	304,627 -17,716	-5%	-$256K	﹤0.01%	2857
2014 Q1	$4.87M	Buy	322,343 +23,506	+8%	+$365K	﹤0.01%	2833
2013 Q4	$4.11M	Buy	298,837 +171,036	+134%	+$2.49M	﹤0.01%	2937
2013 Q3	$2.41M	Buy	+127,801	New	+$2.15M	﹤0.01%	3093

Other funds holding ESPR

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock Fund Advisors's ESPR Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Esperion Therapeutics (ESPR) stake by 13% in Q4 2016, buying an estimated $1.08M and bringing the position to 789,210 shares worth $9.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

BlackRock Fund Advisors first reported a position in ESPR in Q3 2013 and has held it in 14 quarters since. The position peaked at $25.7M in Q2 2015. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

BlackRock Fund Advisors held 789,210 shares of Esperion Therapeutics worth $9.88M as of Q4 2016.
BlackRock Fund Advisors bought 90,435 Esperion Therapeutics shares in Q4 2016, an estimated $1.08M.
Esperion Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2579 holding.
BlackRock Fund Advisors first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Fund Advisors's Esperion Therapeutics position peaked at $25.7M in Q2 2015.
99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.